Boehringer Ingelheim International GmbH - Company Profile
Powered by 
All the sales intelligence you need on Boehringer Ingelheim International GmbH in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Boehringer Ingelheim International GmbH fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Boehringer Ingelheim International GmbH.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures, and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. The company offers an array of products including human diseases, animal health care products, and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cancer, immunology, cardiometabolic diseases, respiratory diseases, and retinal diseases, among others. It also offers animal healthcare products for swine, ruminant, poultry, horses, and pets, among others. The company also offers contract development and manufacturing services to the biopharmaceutical industry. Boehringer is headquartered in Ingelheim am Rhein,Rhineland-Palatinate, Germany.
Headquarters
Germany
Address
Binger Strasse 173, Ingelheim am Rhein, Rheinland-Pfalz, 55216
Website
www.boehringer-ingelheim.com
Telephone
49 6132 770
No of Employees
54,300
Industry
Pharmaceuticals and Healthcare
Revenue (2025)
$31.3B
Boehringer Ingelheim International GmbH premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | Semintra |
| Human Pharmaceuticals: | Contract Manufacturing | BioXcellence |
| Prescription Medicine | Eurican | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In April, the company launched Eko Vet+| CANINEBEAT in partnership with Eko Health. |
| 2026 | Regulatory Approval | In February, the company received an approval the US Food and Drug Administration for HERNEXEOS (zongertinib tablets) for the treatment of adult patients. |
| 2026 | Contracts/Agreements | In January, the company entered into an agreement with Simcere Pharmaceutical Group to develop SIM0709, a pre-clinical TL1A/IL23p19. |
Competitor Comparison
| Key Parameters | Boehringer Ingelheim International GmbH | Eli Lilly and Co | Pfizer Inc | AbbVie Inc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | Germany | United States of America | United States of America | United States of America | Switzerland |
| City | Ingelheim am Rhein | Indianapolis | New York City | North Chicago | Basel |
| State/Province | Rheinland-Pfalz | Indiana | New York | Illinois | Basel-Stadt |
| No. of Employees | 54,300 | 50,605 | 75,000 | 57,000 | 75,267 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Shashank Deshpande | Chairman; Human Pharma Business Unit | Executive Board | 2025 | 53 |
| Michael Schmelmer | Group Functions; Vice Chairman | Executive Board | 2024 | 62 |
| Armin Wiesler | Animal Health Business Unit; Director | Executive Board | 2024 | 52 |
| Paola Casarosa | Innovation Unit; Director | Executive Board | - | - |
| Frank Hubler | Director; Corporate Finance, Accounting, Controlling & Tax | Executive Board | 2019 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer